Typhoid Vi polysaccharide vaccine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Typhoid Vi polysaccharide vaccine
Accession Number
DB10803
Description

Typhoid Vi polysaccharide vaccine is a vaccine that is administered intramuscularly. It is an active immunization for the prevention of typhoid fever caused by S typhi and is approved for use in persons two years of age or older. The vaccine contains the purified cell surface Vi polysaccharide extracted from Salmonella enterica serovar Typhi, S typhi Ty2 strain. The bacterial culture is inactivated in the medium with the capsular polysaccharides precipated from the solution.

Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Inactivated
Synonyms
  • Salmonella typhi TY2 Vi polysaccharide antigen
  • Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain

Pharmacology

Indication
Not Available
Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Abatacept.
AdalimumabThe therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Adalimumab.
AldesleukinThe therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Aldesleukin.
AlefaceptThe therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Alefacept.
AlemtuzumabThe therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Alemtuzumab.
AltretamineThe therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Altretamine.
AmsacrineThe therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Amsacrine.
AnakinraThe therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Anakinra.
Antilymphocyte immunoglobulin (horse)The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Antilymphocyte immunoglobulin (horse).
Antithymocyte immunoglobulin (rabbit)The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

Products

Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
TypherixLiquidIntramuscularGlaxosmithkline Inc2000-11-272017-12-21Canada flag
Typhim ViInjection, solution25 ug/0.5mLIntramuscularA-S Medication Solutions1994-11-28Not applicableUS flag
Typhim ViSolution25 mcg/1IntramuscularSanofi Pasteur Limited1995-12-31Not applicableCanada flag
Typhim ViInjection, solution25 ug/0.5mLIntramuscularA-S Medication Solutions1994-11-28Not applicableUS flag
Typhim ViInjection, solution25 ug/0.5mLIntramuscularSanofi Pasteur Inc.1994-11-28Not applicableUS flag
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
VivaximTyphoid Vi polysaccharide vaccine (25 mcg) + Hepatitis A Vaccine (160 unit)Solution; SuspensionIntramuscularSanofi Pasteur Limited2005-11-09Not applicableCanada flag

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
7194H8W3KT
CAS number
Not Available

References

General References
Not Available
PubChem Substance
347910909
RxNav
807219
AHFS Codes
  • 80:12.00 — Vaccines

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingBasic ScienceFlu caused by Influenza / Healthy Adults / Hepatitis A / Salmonella Typhi Infection1
4CompletedPreventionParatyphoid Fever / Salmonella Typhi Infection2
4RecruitingDiagnosticSpecific Polysaccharide Antibody Deficiency1
4RecruitingPreventionAging / Inflammatory Reaction1
4RecruitingPreventionHealthy Volunteers1
3CompletedPreventionBacterial Infections / Salmonella Infections / Salmonella Typhi Infection1
3CompletedPreventionEncephalitis, Japanese B / Meningococcal Disease / Meningococcal Meningitis / Rabies / Salmonella Typhi Infection / Yellow Fever1
2Active Not RecruitingPreventionPlasmodium Infections1
2Active Not RecruitingPreventionSalmonella Typhi Infection1
2CompletedPreventionDengue Diseases / Dengue Fever / Dengue Hemorrhagic Fever / Dengue Virus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
LiquidIntramuscular
Injection, solutionIntramuscular25 ug/0.5mL
SolutionIntramuscular25 mcg/1
SolutionIntramuscular; Subcutaneous0.025 mg
Injection, solutionIntramuscular; Subcutaneous25 μg/0.5ml
Solution; suspensionIntramuscular
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on December 01, 2015 13:04 / Updated on September 27, 2020 08:17

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates